We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Moves -1.19%: What You Should Know
Read MoreHide Full Article
In the latest trading session, McKesson (MCK - Free Report) closed at $304.02, marking a -1.19% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.25%. Meanwhile, the Dow lost 2.42%, and the Nasdaq, a tech-heavy index, lost 0.48%.
Heading into today, shares of the prescription drug distributor had lost 4.04% over the past month, lagging the Medical sector's loss of 1.96% and outpacing the S&P 500's loss of 5.62% in that time.
McKesson will be looking to display strength as it nears its next earnings release. In that report, analysts expect McKesson to post earnings of $5.29 per share. This would mark a year-over-year decline of 4.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.87 billion, up 1.91% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors might also notice recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.23% higher. McKesson is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 13.23. This valuation marks a discount compared to its industry's average Forward P/E of 18.28.
Also, we should mention that MCK has a PEG ratio of 1.4. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies was holding an average PEG ratio of 2.14 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 236, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Moves -1.19%: What You Should Know
In the latest trading session, McKesson (MCK - Free Report) closed at $304.02, marking a -1.19% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.25%. Meanwhile, the Dow lost 2.42%, and the Nasdaq, a tech-heavy index, lost 0.48%.
Heading into today, shares of the prescription drug distributor had lost 4.04% over the past month, lagging the Medical sector's loss of 1.96% and outpacing the S&P 500's loss of 5.62% in that time.
McKesson will be looking to display strength as it nears its next earnings release. In that report, analysts expect McKesson to post earnings of $5.29 per share. This would mark a year-over-year decline of 4.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $63.87 billion, up 1.91% from the year-ago period.
MCK's full-year Zacks Consensus Estimates are calling for earnings of $23.25 per share and revenue of $264.78 billion. These results would represent year-over-year changes of -1.86% and +0.31%, respectively.
Investors might also notice recent changes to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.23% higher. McKesson is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note McKesson's current valuation metrics, including its Forward P/E ratio of 13.23. This valuation marks a discount compared to its industry's average Forward P/E of 18.28.
Also, we should mention that MCK has a PEG ratio of 1.4. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Dental Supplies was holding an average PEG ratio of 2.14 at yesterday's closing price.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 236, putting it in the bottom 7% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.